Background Data on the prevalence of perennial versus seasonal allergic asthma in Italy
are lacking; moreover, there is limited evidence on the effect of omalizumab on patient …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Severe persistent asthma causes a substantial morbidity and mortality burden and is
frequently inadequately controlled despite intensive guideline-based therapy. Targeting …

OBJECTIVE: To evaluate the 16-and 52-week effectiveness of add-on omalizumab
treatment under real-life heterogeneity in patients, settings, and physicians in an open-label …

Omalizumab (Xolair®) is a subcutaneously administered monoclonal antibody that targets
circulating free IgE and prevents its interaction with the high-affinity IgE receptor (FCεRI) …

Omalizumab is the first licensed anti‐immunoglobulin (Ig) E antibody shown to be effective
for treatment of allergic (IgE‐mediated) asthma. Recent international guidelines recommend …

Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now
well recognized that asthma is a chronic inflammatory disease of the airways. The …

BACKGROUND: In a 1-year, randomized, open-label study in patients with moderate-to-
severe allergic (immunoglobulin E (IgE)-mediated) asthma, adding omalizumab to best …

Background Recent efficacy studies of asthma biologics have included highly enriched
patient populations. Using a similar approach, we examined factors that predict response to …

BACKGROUND: Previous reports show that addition of omalizumab to standard therapy
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …